In a notice, the NIH said that indirect costs accounted for around $9 billion of its $35 billion funding spend in fiscal 2023, and the current rate has been far higher than what is allowed by other ...

The downsizing of health federal agencies comes after Trump threatened to pull the US out of the World Health Organization ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Phil Johnson started about four months ago as chief commercial officer at Evidation. He sat down on the sidelines of JP ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...

I’ve got my eye on four trends – the maturation of AI-powered drug development, fierce competition in the GLP-1 space, the ...

Digital health company Liva Healthcare has acquired UK-based Momenta, a provider of digital, virtual, and in-person healthy ...

For its part, Hims & Hers maintains that the 'Sick of the System' ad – its first for a Super Bowl – "highlights the growing ...